# A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Source: https://onco.cc/trials/nct05276726/  
OnCo record `nct05276726` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Glecirasib in non-small-cell lung cancer and small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.

## Summary

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 is a phase 1/2 interventional study registered as NCT05276726 by Allist Pharmaceuticals, Inc., with 104 participants planned, started 2022-08-17 and due to reach its primary completion in 2027-08. Interventions recorded: JAB 21822. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05276726
- Phase: 1/2
- Setting: A Phase Ib/II ,Single Arm, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of JAB-21822 in Advanced or Metastatic Non-small Cell Lung Cancer With a KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
- Sponsor: Allist Pharmaceuticals, Inc.
- Enrolled: 104

## Sources

- ClinicalTrials.gov NCT05276726: https://clinicaltrials.gov/study/NCT05276726

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Glecirasib](https://onco.cc/drugs/glecirasib/)
- companies: [Shanghai Allist Pharmaceuticals](https://onco.cc/companies/allist/)

---
JSON: https://onco.cc/api/v1/entities/nct05276726.json